

## LETTER TO THE EDITOR

**Reply to Cooper's letter in reference to: Cardiopulmonary exercise testing with supramaximal verification produces a safe and valid assessment of  $\text{VO}_{2\text{max}}$  in people with cystic fibrosis.**

Adam J. Causer<sup>1,2</sup>, Janis K. Shute<sup>3</sup>, Michael H. Cummings<sup>4</sup>, Anthony I. Shepherd<sup>1</sup>, Victoria Bright<sup>2</sup>, Gary Connett<sup>5</sup>, Mark I. Allenby<sup>2</sup>, Mary P. Carroll<sup>2</sup>, Thomas Daniels<sup>2</sup>, and Zoe L. Saynor<sup>1,2\*</sup>.

<sup>1</sup> Department of Sport and Exercise Science, Faculty of Science, University of Portsmouth, Portsmouth, UK.

<sup>2</sup> Cystic Fibrosis Unit, University Hospital Southampton NHS Foundation Trust, Southampton, UK.

<sup>3</sup> School of Pharmacy and Biomedical Sciences, Faculty of Science, University of Portsmouth, Portsmouth, UK.

<sup>4</sup> Department of Diabetes and Endocrinology, Queen Alexandra Hospital, Portsmouth, UK.

<sup>5</sup> National Institute for Health Research, Southampton Biomedical Research Centre, Southampton Children's Hospital, UK

\*Correspondence to Dr. Z. L. Saynor, Department of Sport and Exercise Science, Faculty of Science, University of Portsmouth, Portsmouth, Hampshire, UK, PO1 2ER.

Tel: +44 (0)2392 843080

Email: zoe.saynor@port.ac.uk

## LETTER TO THE EDITOR

We thank Prof. Cooper for his comments (2) on our recent article (1), in which he questions the rationale for conducting supramaximal verification ( $S_{\max}$ ) and, indeed, cardiopulmonary exercise testing (CPET) in people with cystic fibrosis (CF). Whilst he should be commended on his vision to further develop the exercise testing toolkit for use in a clinical setting, this is disparate to the aims of our investigation. Specifically, our study focused on the added value of using  $S_{\max}$  to improve confidence in the measurement of maximal parameters during incremental CPET, a procedure recognized and advocated by the European Respiratory and CF Societies (3), due to its functional and prognostic evaluative ability.

Several of Prof. Cooper's viewpoints are worthy of challenge. Firstly, Prof. Cooper misinterpreted our article, to surmise that inaccuracies during incremental testing "can be 'corrected' by an additional test in which the participant exercises to exhaustion at a supramaximal constant work-rate" (2). To reiterate the premise of  $S_{\max}$ , this recognized concept (5) enables us to 1) confirm a maximal effort has been provided or, importantly, 2) demonstrate that an incremental exercise test effort was submaximal. Given the reported validity concerns surrounding secondary verification criteria (4), this is a simple extension that may "improve the practitioner's confidence that a true maximal effort has been given by the participant" (1). Indeed, we reported a case whereby  $S_{\max}$  elevated  $\dot{V}O_{2\text{peak}}$  24.4% higher than the preceding 'exhaustive' incremental cycling test. We acknowledge that the cut-off criteria used was based on the typical error for  $\dot{V}O_{2\text{max}}$  in children and adolescents with CF, this threshold (9%) is comparable to the 10% used in Prof. Cooper's calculations, and the data suggested by his simulation model would still not account for such a large increase in exercise capacity.

Prof. Cooper also raises concerns about the safety of  $S_{\max}$ . We acknowledge within our paper that cases of hypoxemia did occur during  $S_{\max}$ , however, the pertinent finding was that its addition did not significantly increase the frequency or magnitude of desaturation compared with incremental cycling alone. Given the pulmonary consequences of CF, cases of exercise-induced hypoxemia will of course occur. However, CPET allows us to identify the exercise intensity at which this occurs, which can be "useful in managing their daily life activities and benefiting their health", a recommendation advocated by Prof. Cooper.

Lastly, we acknowledge Prof. Cooper's viewpoint that "adding uncomfortable procedures to an already challenging and time consuming test is not likely to advance CPET in clinical research or practice". However, as the evidence supporting the value of  $S_{\max}$  continues to grow (5), we feel this additional time (of ~ 20 minutes) is time well spent. Furthermore, considering patients' feedback, data from our research group demonstrated that the majority of young people with CF (75%) enjoyed CPET with  $S_{\max}$ , and completing the test empowered 50% of them to seek advice regarding physical activity (4). Therefore, we would conclude that CPET with  $S_{\max}$ , when interpreted correctly, may actually fit the criteria Prof. Cooper recommends for modern exercise testing (2).

(500 words)

## References

1. **Causer AJ, Shute JK, Cummings MH, Shepherd AI, Bright V, Connett G, Allenby MI, Carroll MP, Daniels T, Saynor ZL.** Cardiopulmonary exercise testing with supramaximal verification produces a safe and valid assessment of  $\dot{V}O_{2\max}$  in people with cystic fibrosis. *J. Appl. Physiol.* (August 2, 2018). doi: 10.1152/jappphysiol.00454.2018.
2. **Cooper DM.** Supramax Exercise Testing in Cystic Fibrosis: Not Ready for Prime Time. "Letter to The Editor Regarding Causer et al. 'Cardiopulmonary Exercise Testing With Supramaximal Verification Produces A Safe And Valid Assessment Of  $\dot{V}O_{2\max}$  In People With Cystic Fi. *J. Appl. Physiol.*
3. **Hebestreit H, Arets HGM, Aurora P, Boas S, Cerny F, Hulzebos EHJ, Karila C, Lands LC, Lowman JD, Swisher A, Urquhart DS.** Statement on exercise testing in cystic fibrosis. *Respiration* 90: 332–351, 2015.
4. **Keenan V, Payne S, Yonge C, Saynor Z, Legg J, Connett G.** 254 Feasibility of implementing cardiopulmonary exercise testing in a regional paediatric cystic fibrosis centre in the UK. *J Cyst Fibros* 16: S127, 2017.
5. **Poole DC, Jones AM.** Measurement of the maximum oxygen uptake  $\dot{V}O_{2\max}$  :  $\dot{V}O_{2\text{peak}}$  is no longer acceptable. *J Appl Physiol* 122: 997–1002, 2017.